These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thiophosphorylated RCM-lysozyme, an active site-directed protein tyrosine phosphatase inhibitor, inhibits G2/M transition during mitotic cell cycle and uncouples MPF activation from G2/M transition.
    Author: Hiriyanna KT, Buck WR, Shen SS, Ingebritsen TS.
    Journal: Exp Cell Res; 1995 Jan; 216(1):21-9. PubMed ID: 7813623.
    Abstract:
    Microinjection of thiophosphotyrosylated RCM-lysozyme (TRCML), a potent and specific inhibitor of protein tyrosine phosphatases (PTPs) into sea urchin (Lytechinus pictus) eggs prior to fertilization inhibited the first zygotic cell division in a concentration-dependent fashion. Microinjection of TRCML at varying times after fertilization indicated that at least one site of action is late in the first cell cycle near the G2/M boundary. In order to further study the mechanism for the TRCML effect, a cell-free cell cycling system prepared from electrically activated Xenopus eggs was used. The addition of TRCML to cycling extracts delayed the entrance and progression of extracts through mitosis, as indicated by the inhibition of chromatin condensation, nuclear envelope breakdown, M-phase-promoting factor (MPF) inactivation, and cyclin degradation. Surprisingly, TRCML did not inhibit MPF activation. These results suggest that (1) the target(s) of TRCML lies in late G2- or early M-phase before the onset of metaphase, (2) TRCML uncouples MPF activation from progression through M-phase, and (3) there is a potential involvement of a novel PTP(s) in the control of the cell cycle which may act either downstream of the MPF activation or alternatively in an additional but essential mitotic pathway that is parallel to the MPF activation pathway.
    [Abstract] [Full Text] [Related] [New Search]